Opdivo (nivolumab) • 5-fluorouracil • capecitabine • mitomycin • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)

Phase 2

National Cancer Institute (NCI)

Active, not recruiting

Phase 2

National Cancer Institute (NCI)

Active, not recruiting

Last update posted :

02/06/2025

Initiation :

08/17/2015

Primary completion :

12/31/2025

Completion :

12/31/2025

MSI • CD4

PD-L1 expression

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) (THOR-2) (NCT04172675)

Phase 2

Janssen Research & Development, LLC

Active, not recruiting

Phase 2

Janssen Research & Development, LLC

Active, not recruiting

Last update posted :

02/03/2025

Initiation :

02/28/2020

Primary completion :

07/12/2024

Completion :

03/03/2025

FGFR

FGFR mutation • FGFR fusion

gemcitabine • Balversa (erdafitinib) • mitomycin

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (SHIELD-RT) (NCT03775265)

Phase 3

National Cancer Institute (NCI)

Active, not recruiting

Phase 3

National Cancer Institute (NCI)

Active, not recruiting

Last update posted :

06/07/2024

Initiation :

06/03/2019

Primary completion :

06/01/2027

Completion :

06/01/2027

PD-L1 • CD4

cisplatin • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • mitomycin • Jelmyto (mitomycin urothelial gel) • fluorouracil topical

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer (NCT04107077)

Phase 2

University of Chicago

Recruiting

Phase 2

University of Chicago

Recruiting

Last update posted :

05/14/2024

Initiation :

03/14/2024

Primary completion :

06/01/2024

Completion :

06/01/2025

PD-L1

PD-L1 expression

cisplatin • mitomycin

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis (NCT04858009)

Phase 2

Mayo Clinic

Recruiting

Phase 2

Mayo Clinic

Recruiting

Last update posted :

01/19/2024

Initiation :

01/05/2024

Primary completion :

05/01/2025

Completion :

05/01/2026

KRAS

cisplatin • paclitaxel • albumin-bound paclitaxel • mitomycin • Jelmyto (mitomycin urothelial gel)

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group (RADIANCE) (NCT04230759)

Phase 2

Goethe University

Active, not recruiting

Phase 2

Goethe University

Active, not recruiting

Last update posted :

12/04/2023

Initiation :

01/07/2020

Primary completion :

12/31/2026

Completion :

03/31/2027

CD4

Imfinzi (durvalumab) • 5-fluorouracil • mitomycin

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study (NCT04166318)

Phase 2

ECOG-ACRIN Cancer Research Group

Recruiting

Phase 2

ECOG-ACRIN Cancer Research Group

Recruiting

Last update posted :

06/22/2023

Initiation :

01/02/2020

Primary completion :

12/31/2029

Completion :

12/31/2029

CD4

5-fluorouracil • capecitabine • mitomycin • fluorouracil topical

Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy (WUHIPEC02) (NCT04845490)

Phase 2

Wuhan Union Hospital, China

Not yet recruiting

Phase 2

Wuhan Union Hospital, China

Not yet recruiting

Last update posted :

02/21/2022

Initiation :

09/01/2022

Primary completion :

09/01/2023

Completion :

09/01/2026

CD8 • IFNG • TNFA • CD4 • IL2

mitomycin • lobaplatin (D19466)

Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer (NCT04747717)

Phase N/A

N.N. Petrov National Medical Research Center of Oncology

N.N. Petrov National Medical Research C...

Recruiting

Phase N/A

N.N. Petrov National Medical Research Center of...

Recruiting

Last update posted :

02/11/2021

Initiation :

10/01/2020

Primary completion :

10/01/2022

Completion :

10/01/2025

BRCA1 • BRCA2

BRCA2 mutation

cisplatin • carboplatin • paclitaxel • mitomycin

Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene (NCT00386399)

Phase 2

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sidney Kimmel Comprehensive Cancer Cent...

Withdrawn

Phase 2

Sidney Kimmel Comprehensive Cancer Center at Jo...

Withdrawn

Last update posted :

07/12/2018

Initiation :

10/01/2006

Primary completion :

02/01/2008

Completion :

02/01/2008

BRCA2

BRCA2 mutation

mitomycin

A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma (NCT00183885)

Phase 2

University of Southern California

Unknown status

Phase 2

University of Southern California

Unknown status

Last update posted :

05/16/2018

Initiation :

10/18/2004

Primary completion :

05/28/2013

Completion :

05/28/2019

AFP

cisplatin • mitomycin

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors (NCT01017640)

Phase 1

National Cancer Institute (NCI)

Completed

Phase 1

National Cancer Institute (NCI)

Completed

Last update posted :

07/11/2016

Initiation :

10/01/2009

Primary completion :

05/01/2016

ER • BRCA • FANCD2

BRCA mutation

veliparib (ABT-888) • mitomycin

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer (NCT01296763)

Phase 1/2

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sidney Kimmel Comprehensive Cancer Cent...

Completed

Phase 1/2

Sidney Kimmel Comprehensive Cancer Center at Jo...

Completed

Last update posted :

03/22/2016

Initiation :

01/01/2011

Primary completion :

01/01/2014

Completion :

02/01/2016

BRCA

Lynparza (olaparib) • cisplatin • irinotecan • mitomycin

Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic (NCT01703910)

Phase 2

Centro Nacional de Investigaciones Oncologicas CARLOS III

Centro Nacional de Investigaciones Onco...

Completed

Phase 2

Centro Nacional de Investigaciones Oncologicas ...

Completed

Last update posted :

10/09/2015

Initiation :

11/01/2012

Primary completion :

11/01/2012

Completion :

12/01/2014

KRAS

Erbitux (cetuximab) • cisplatin • erlotinib • dasatinib • gemcitabine • sorafenib • paclitaxel • docetaxel • 5-fluorouracil • doxorubicin hydrochloride • capecitabine • pemetrexed • oxaliplatin • etoposide IV • irinotecan • vinorelbine tartrate • topotecan • mitomycin • Tomudex (raltitrexed)

mitomycin

Trials

Trials